FrieslandCampina Ingredients says it is one step closer to “final nutrition fortifier” from the Chinese Ministry of Agriculture and Rural Affairs (MARA) for its Lacto-N-Tetraose (LNT) ingredient.
Photo © stock.adobe.com/ucchie79
FrieslandCampina Ingredients has announced that its product strain of Lacto-N-Tetraose (LNT) has received approval from the Chinese Ministry of Agriculture and Rural Affairs (MARA). According to the company’s press release, the ingredient will now move to the final stage of the approval process, opening the door for its human milk oligosaccharide (HMO) ingredients to enter the Chinese market. Prior to this, FrieslandCampina’s Aequival 2’-fucosyllactose (2’-FL) ingredient received MARA approval in October of 2023. Once these ingredients receive “final nutrition fortifier” approval, FrieslandCampina says it will be the only company to provide both HMO and galacto-oligosaccharides (GOS) in China.
The company has also announced the self-affirmed GRAS (generally recognized as safe) status of its Aequival LNT in the United States. “This news marks a significant milestone for us as a company and for the early life nutrition sector in China and the US,” says Cindy Zhao, general manager of FrieslandCampina Ingredients China, in a press release. “Both the MARA and self-affirmed GRAS approvals of the production strain of our LNT brings us one step closer to meeting consumers’ increasing demand for premium, gut-supporting infant milk formulas that provide benefits for babies when breastfeeding isn’t an option.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.